Clinical Trials Browser

Interventional × lenvatinib × 30 days × Clear all

NCT04938817 2026-05-27

KEYNOTE-B98

Phase 1/2 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT07495579 2026-05-27

REVIVE

Phase 2 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT03486873 2026-05-26

MK-3475-587

Phase 3 Recruiting

Other hematologic neoplasm

Hematologic Neoplasms

NCT05319730 2026-05-26

MK-3475-06B

Phase 1/2 Recruiting

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT05585580 2026-05-26

Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy

Phase 2 Active not recruiting

Gastrointestinal

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

NCT07405164 2026-05-26

MK-6482-043

Phase 3 Recruiting

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT06187961 2026-05-22

CCGLC-011

Phase 2 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT07493668 2026-05-22

FLEX-HCC

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT04626479 2026-05-18

MK-3475-03A

Phase 1/2 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT07594015 2026-05-18

Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-based Doublet and Immunotherapy

Phase 2 Recruiting

Endometrial Neoplasms

NCT04977453 2026-05-15

Keynote B59

Phase 1/2 Recruiting

GenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Neoplasm Metastasis

NCT04246177 2026-05-14

LEAP-012

Phase 3 Completed

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Hepatocellular

NCT06110793 2026-05-13

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

Phase 1/2 Recruiting

Breast Neoplasms

NCT07081633 2026-05-12

TREMENDOUS-2

Phase 2 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT04848337 2026-05-11

PLANE-PC

Phase 2 Active not recruiting

45 enrolled 8 charts

Neuroendocrine Tumors

NCT05903833 2026-05-11

PIERCE

Phase 2 Recruiting

Vulvar Neoplasms

NCT07571551 2026-05-11

TRIPLE-PATH

Phase 2 Recruiting

Carcinoma, Renal Cell

NCT04164199 2026-05-08

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Phase 3 Active not recruiting

Advanced Malignancies

NCT07384416 2026-05-08

QL1706 Plus Lenvatinib in Previously Treated Penile Cancer

Phase 2 Recruiting

Penile Neoplasms

NCT04626518 2026-05-06

KEYMAKER-U03

Phase 1/2 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT04736706 2026-05-06

MK-6482-012

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT06266338 2026-05-06

Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)

Phase 2 Recruiting

Uterine Cervical Neoplasms

NCT04199104 2026-05-05

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)

Phase 3 Completed

511 enrolled 20 charts

Squamous Cell Carcinoma of Head and Neck

NCT04586231 2026-05-05

MK-6482-011

Phase 3 Active not recruiting

Carcinoma, Renal Cell

NCT07014150 2026-05-05

Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT03797326 2026-05-04

LEAP-005

Phase 2 Completed

611 enrolled 27 charts

BreastCNSGastrointestinalGynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Biliary Tract Neoplasms, Glioblastoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT05327686 2026-05-04

SAMURAI

Phase 2 Recruiting

Carcinoma, Renal Cell